ACTIN Report (research use only)

PATIENT
ACTN01029999

REPORT DATE
17-Jun-2024

Gender: Male | Birth year: 1950 | WHO: 1

Tumor: Skin - Melanoma | Lesions: Brain, CNS, Liver, Lung, Test Lesion, Lymph nodes (abdominal, cervical and supraclavicular) | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history	2019	Therapy1
	?-6/2020	Therapy2
	8/2020-3/2021	Therapy3
	2022	Clinical trial: Trial1
	2022	Clinical trial: Trial1 (3 cycles, stop reason: toxicity)
	2022	Clinical trial (tr2): Trial2 (3 cycles, stop reason: toxicity)
	2022	Clinical trial: Trial4 (adjuvant, 1 cycle, stop reason: toxicity)
	2022	Clinical trial: Trial5 (adjuvant and consolidation, stop reason: toxicity)
	2023	Therapy4
	Date unknown	Therapy
Relevant other oncological history	2022	Clinical trial (details unknown)
Previous primary tumor	Lung adenocarcinoma (diagnosed 6/2021, considered non-active)	
Relevant non-oncological history	Pancreatitis Coronary artery bypass graft (CABG)	

Recent molecular results

Hartwig WGS of ACTN01029999 (12-Jun-2024)

Biopsy location	Liver (purity 98%)
Molecular tissue of origin prediction	Melanoma (100%)
Tumor mutational load / burden	TML high (185) / TMB high (13.7)
Microsatellite (in)stability	Stable
HR status	Proficient (0.45)
Genes with high driver mutation	BRAF
Amplified genes	MYC
Deleted genes	PTEN
Homozygously disrupted genes	PTEN
Gene fusions	EML4 - ALK fusion
Virus detection	HPV positive (3 int. detected)
Potentially actionable events with medium/low driver:	PTEN disruption

Approved treatments considered eligible

Treatment
Not yet determined

EMC trials that are open and considered eligible and currently have slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
Test Trial 1 TEST-1 (Phase 1)	Cohort B	None	Undetermined SOC exhaustion

EMC trials that are open and considered eligible but currently have no slots available (2 cohorts from 2 trials)

Trial	Cohort	Molecular	Warnings
Test Trial 1 TEST-1 (Phase 1)	Cohort A	MSI	Undetermined SOC exhaustion
Test Trial 2 TEST-2	Cohort A	MSI	None

trial kb trials potentially eligible based on molecular results which are potentially recruiting in The Netherlands (2)

Event	Trial title	NCT number
TMB High, TML High, PTEN hom disruption, PTEN disruption, EML4 - ALK fusion, HPV positive	treatment	NCT00000001
MYC amp	A Phase 1 Study of XYXYXY, a T-Cell-Redirecting Agent Targeting Z, for Advanced Prostate Cancer	NCT00000003

trial kb trials potentially eligible based on molecular results which are potentially recruiting outside the Netherlands (1)

Event	Trial title	NCT number	Country
PTEN del	A Phase 1/2 Randomized Study to Evaluate the Safety and Efficacy of treatment X Plus ... Y, as First-Line Treatment for Participants With Advanced Solid Tumor (acronym)	NCT00000020	Belgium, Germany

Currently only Belgian and German trials are supported

Molecular Details

Hartwig WGS (ACTN01029999T, 12-Jun-2024)

General

Purity	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
98%	**High (185)**	**High (13.7)**	Stable	Proficient (0.45)	*1_HOM (Normal function)	*1_HET (Normal function), *28_HET (Reduced function)

Predicted tumor origin

	1. Melanoma
Combined prediction score	**100%**
This score is calculated by combining information on:	
(1) SNV types	98%
(2) SNV genomic localisation distribution	99%
(3) Driver genes and passenger characteristics	97%

Other cohorts have a combined prediction of 0% or lower

Drivers

Type	Driver	Driver likelihood	Trials in EMC	Trials in trial kb	Best evidence in kb	Resistance in kb
Mutation (Hotspot)	BRAF V600E (4/6 copies)	High			Approved	
Amplification	MYC amp, 38 copies	High		NCT00000003		
Loss	PTEN del, 0 copies	High		NCT00000020		
Known fusion	EML4 - ALK fusion, exon 6 - exon 20	High		NCT00000001	Approved	Known resistance
Disruption (homozygous)	PTEN	High		NCT00000001	Approved	Known resistance
Virus	HPV positive, 3 integrations detected	High		NCT00000001	Approved	Known resistance
Disruption	PTEN, DEL (1.1 disr. / 1.8 undisr. copies)	Low		NCT00000001	Approved	Known resistance

Clinical Details

Clinical summary

Relevant systemic treatment history	**2019**	**Therapy1**
	?-6/2020	**Therapy2**
	8/2020-3/2021	**Therapy3**
	2022	**Clinical trial: Trial1**
	2022	**Clinical trial: Trial1 (3 cycles, stop reason: toxicity)**
	2022	**Clinical trial (tr2): Trial2 (3 cycles, stop reason: toxicity)**
	2022	**Clinical trial: Trial4 (adjuvant, 1 cycle, stop reason: toxicity)**
	2022	**Clinical trial: Trial5 (adjuvant and consolidation, stop reason: toxicity)**
	2023	**Therapy4**
	Date unknown	**Therapy**
Relevant other oncological history	**2022**	**Clinical trial (details unknown)**
Previous primary tumor	**Lung adenocarcinoma (diagnosed 6/2021, considered non-active)**	
Relevant non-oncological history	**Pancreatitis** **Coronary artery bypass graft (CABG)**	

Patient current details (07-Jun-2024)

Unresolved toxicities grade => 2	**Fatigue (2)**
Cancer-related complications	**Ascites**
Known allergies	**Wasps (Environment)**
Recent surgeries	**18-May-2024**

Tumor details (07-Jun-2024)

Measurable disease	**Yes**
CNS lesion status	**Present CNS lesions (active)**
Brain lesion status	**Present brain lesions (not active)**

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
None					

Blood transfusions

Product	Date
Thrombocyte concentrate	02-Jun-2024

Trial Matching Summary

EMC trials and cohorts that meet molecular requirements and may be eligible, but are closed (0)

None

EMC trials and cohorts that are open but considered ineligible (1)

Trial	Cohort	Molecular	Ineligibility reasons
Test Trial 2 TEST-2	Cohort B	None	Pembrolizumab treatment